Management of post-chemotherapy residual masses in advanced seminoma

被引:62
|
作者
Fléchon, A [1 ]
Bompas, E [1 ]
Biron, P [1 ]
Droz, JP [1 ]
机构
[1] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France
来源
JOURNAL OF UROLOGY | 2002年 / 168卷 / 05期
关键词
testes; seminoma; drug therapy; cisplatin; neoplasm; residual;
D O I
10.1016/S0022-5347(05)64275-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We studied the resection of post-chemotherapy residual masses (20% to 80%) of advanced seminoma complicated by extensive fibrosis, in which active disease appears in 10% to 20% of cases. Materials and Methods: We retrospectively analyzed (1986 to 2000) residual mass evolution according to size in 79 platinum treated patients. Results: There was an evaluable response in 78 patients, including toxic death in 1 after 1 chemotherapy cycle, a complete response in 34 (after chemotherapy in 15 and after complete residual mass resection in 19), a marker negative partial response in 42 (incomplete residual mass resection in 8), stable and progressive disease in 1 each. In 15 of 31 patients the resected residual mass was 3 cm. or greater, whereas in 12 of 29 it was less than 3 cm. No surgery was performed for 3 residual masses of unknown size. Of the 42 residual masses 21 disappeared at a median of 12.5 months. Progression occurred at the initial tumor site in 11 of 13 patients after a median of 3.5 months, including 3 with a complete response, 8 with a marker negative partial response (residual mass 3 cm. or greater in 3, less than 3 cm. in 4 and unknown size in 1) and treatment failure in 2 (residual mass 3 cm. or greater). At a median followup of 36.4 months 67 patients survived (no disease progression in 56 and nonevolving residual masses in 11), while 12 had died including 9 of progressive disease 1 of toxicity and 2 of other causes. Conclusions: In our study there was incomplete surgical resection in 30% of cases. Relapse in 16.6% of cases occurred rapidly after the end of chemotherapy. Viable cells were only noted in residual masses 3 cm. or greater (13%) and 50% of residual masses disappeared during surveillance. We intend. to perform a prospective cohort study with close followup of patients with residual masses less than 3 cm. using an indication for surgery tailored to positron emission tomography findings in those with residual masses 3 cm. or greater.
引用
收藏
页码:1975 / 1979
页数:5
相关论文
共 50 条
  • [21] Post-chemotherapy retroperitoneal resection of residual masses in germ cell cancer with modified template resection
    Pfister, David
    Ohlmann, Carsten H.
    Pfister, David
    Thuer, David
    Sahi, Dina
    Heidenreich, Axel
    JOURNAL OF UROLOGY, 2007, 177 (04): : 330 - 330
  • [22] Post-chemotherapy retroperitoneal resection of residual masses in germ cell cancer with modified template resection
    Pfister, D.
    Ohlmann, C.
    Thueer, D.
    Sahi, D.
    Heidenreich, A.
    ONKOLOGIE, 2008, 31 : 184 - 184
  • [23] GALLIUM SCANS IN THE EVALUATION OF RESIDUAL MASSES AFTER CHEMOTHERAPY FOR SEMINOMA
    WARREN, GP
    EINHORN, LH
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) : 2784 - 2788
  • [24] Optimal management of residual mass after chemotherapy in advanced seminoma: There is time for everything
    Culine, S
    Droz, JP
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2884 - 2885
  • [25] Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?
    Russell, Christopher M.
    Sharma, Pranav
    Agarwal, Gautum
    Fisher, John S.
    Richard, George J.
    Spiess, Philippe E.
    Pow-Sang, Julio M.
    Poch, Michael A.
    Sexton, Wade J.
    CANADIAN JOURNAL OF UROLOGY, 2016, 23 (01) : 8127 - 8134
  • [26] Resection of post-chemotherapy residual masses (RMs) in patients with advanced non-seminomatous germ cell tumors (NSGCT): prediction of outcomes
    Mediano Rambla, M.
    Thiery-Vuillemin, A.
    Alonso, M.
    Ocon, E.
    Conde, M.
    Sancho, P.
    Osman, I.
    Robles, C.
    Medina, R.
    Duran, I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S650 - S650
  • [27] IS PERCENT SEMINOMA ASSOCIATED WITH INTRAOPERATIVE MORBIDITY DURING POST-CHEMOTHERAPY RPLND?
    Sharma, Pranav
    Zargar-Shoshtari, Kamran
    Poch, Michael
    Powsang, Julio
    Sexton, Wade
    Spiess, Philippe
    Gilbert, Scott
    JOURNAL OF UROLOGY, 2016, 195 (04): : E839 - E839
  • [28] The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma - Comment
    Gonzalgo, Mark L.
    JOURNAL OF UROLOGY, 2008, 179 (03): : 940 - 940
  • [29] Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT)
    Kuczyk, M
    Machtens, S
    Stief, C
    Jonas, U
    INTERNATIONAL JOURNAL OF CANCER, 1999, 83 (06) : 852 - 855
  • [30] The role of 18FDG PET/CT in the evaluation of post chemotherapy residual masses in patients with seminoma
    Rondogianni, P.
    Panagiotidis, E.
    Skoura, E.
    Exarchos, D.
    Giannopoulou, C.
    Chroni, P.
    Datseris, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S343 - S343